Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of its new predictive modelling solution, which predicts human pharmacokinetics directly from chemical structure. Pharmacokinetics is defined as the study of the concentration of drug in the body over time, and is based on the absorption, distribution, metabolism and excretion of a drug.
Our new chemPK™ solution has been developed by Cyprotex’s Scientific Computing Team using PBPK (physiologically based pharmacokinetic) predictive modelling. Cyprotex have considerable expertise in this technique, having previously developed and launched the proprietary modelling software, Cloe® PK and Cloe® HIA. chemPK™ is a virtual screening tool meaning that it can be employed before chemical synthesis of a molecule and does not require any data inputs. This provides significant cost benefits and can be used as an early stage filter for directing chemistry and prioritising in vitro screening taking account of the predicted human pharmacokinetics.
chemPK™ is unique in that the model has been optimised directly on human clinical data, and so provides a more robust approach as compared to alternative models that use QSAR (quantitative structure activity relationship)-based methods for predicting their input parameters. chemPK™ is implemented as a collection of nodes for the widely used KNIME workflow management platform, enabling its use in either desktop or server environments, and facilitating its interaction with many other cheminformatics, analytics and modelling tools.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: ‘Our new chemPK™ solution provides significant advantages over existing products in the market. It will provide our customers with an insight into the expected exposure of a molecule in the human body at an early stage enabling them to only synthesise compounds with the best chance of success.’
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.